Moreover, TRK (tropomyosin receptor kinase) inhibitors such as larotrectinib and entrectinib are symbolic of a new era, in which tumor-agnostic therapeutics take the lead for cancer drug therapy. This evidence concerns the gene NTRK1 and neoplasm.